Targeted News Service

AstraZeneca: Datroway Approved in the US for Patients With Previously Treated Metastatic HR-Positive, HER2-Negative Breast Cancer
January 18, 2025

WILMINGTON, Delaware, Jan. 18 (TNSjou) -- AstraZeneca, a biopharmaceutical company, issued the following news release:

* * *

First approval in the US for AstraZeneca and Daiichi Sankyo's DATROWAY based on TROPION-Breast01 results showing 37% reduction in the risk of disease progression or death vs. chemotherapy

DATROWAY is the eighth new medicine of the 20 AstraZeneca has set out to deliver by 2030

* * *

DATROWAY (datopotamab . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your Affiliation	Government Newspaper / Media Business Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions or comments:

Click here for more information about our products

Existing Customer Login

Targeted News Service Document Request Form